Aspirin for Treatment of Multiple Sclerosis-Related Fatigue

Sponsored by Mayo Clinic

Phase Quota
Phase 3

The purpose of this study is to determine whether aspirin is effective for treatment of fatigue caused by multiple sclerosis (MS).

Study Start Date: March 2007

Estimated Completion Date: May 2014

Specialties: Psychiatry: Psychotherapy/analysis Neurology: Demyelinating Disorders,Neuro/Psych pharmacology Pharmacy: Neuro/Psych pharmacology


  • Drug: Aspirin

Inclusion criteria

  • Confirmed relapsing-remitting or secondary progressive multiple sclerosis
  • Ambulatory for distance of at least 100 m without gait assistance
  • Persistent fatigue for at least 8 weeks that is not attributable to causes other than MS, and
  • Will be able to complete questionnaires and cognitive testing

Exclusion criteria

  • Other evident causes for fatigue
  • Recent MS disease activity or specific changes in MS therapy
  • Current use of ASA or other NSAIDs
  • Use of CNS stimulants
  • Use of medications that contraindicate the use of ASA, ASA allergy or sensitivity
  • History of peptic ulcer disease or GI bleed
  • Alcohol abuse
  • Pregnancy, and
  • Laboratory abnormalities

Study Locations And Contact Information

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit to find out how you can feature this clinical trial.